Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 2;13(12):2270.
doi: 10.3390/genes13122270.

No Evidence to Support a Causal Relationship between Circulating Adiponectin Levels and Ankylosing Spondylitis: A Bidirectional Two-Sample Mendelian Randomization Study

Affiliations

No Evidence to Support a Causal Relationship between Circulating Adiponectin Levels and Ankylosing Spondylitis: A Bidirectional Two-Sample Mendelian Randomization Study

Jiale Xie et al. Genes (Basel). .

Abstract

Based on previous observational studies, the causal association between circulating adiponectin (CA) levels and ankylosing spondylitis (AS) risk remains unclear. Therefore, this study aims to investigate whether CA levels are related to the risk of AS. We carried out a bidirectional two-sample Mendelian randomization (MR) analysis to examine the causal correlation between CA levels and AS via published genome-wide association study (GWAS) datasets. Single-nucleotide polymorphisms (SNPs) related to CA levels were derived from a large GWAS that included 39,883 individuals of European descent. SNPs related to AS were obtained from the FinnGen consortium (2252 cases and 227,338 controls). The random-effects inverse variance weighted (IVW) method was the primary method utilized in our research. We also used four complementary approaches to improve the dependability of this study (MR-Egger regression, Weighted median, Weighted mode, and Simple mode). Random-effects IVW (odds ratio [OR], 1.00; 95% confidence interval [CI], 0.79-1.27, p = 0.984) and four complementary methods all indicated that genetically predicted CA levels were not causally related to the risk of AS. In reverse MR analysis, there is little evidence to support the genetic causality between the risk of AS and CA levels.

Keywords: Mendelian randomization; ankylosing spondylitis; causal; circulating adiponectin levels; single-nucleotide polymorphisms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that this study was conducted without any potential conflict of interest.

Figures

Figure 1
Figure 1
An overview of the study design. SNP, single-nucleotide polymorphism; BMI, body mass index.
Figure 2
Figure 2
The association between circulating adiponectin levels and the risk of ankylosing spondylitis is presented in (A) a forest plot, (B) a leave-one-out sensitivity analysis, (C) a scatter plot, and (D) a funnel plot.
Figure 3
Figure 3
The association between the risk of ankylosing spondylitis and circulating adiponectin levels is presented in (A) a forest plot, (B) a leave-one-out sensitivity analysis, (C) a scatter plot, and (D) a funnel plot.

Similar articles

References

    1. Mauro D., Thomas R., Guggino G., Lories R., Brown M.A., Ciccia F. Ankylosing spondylitis: An autoimmune or autoinflammatory disease? Nat. Rev. Rheumatol. 2021;17:387–404. - PubMed
    1. Shao F., Liu Q., Zhu Y., Fan Z., Chen W., Liu S., Li X., Guo W., Feng G.-S., Yu H., et al. Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis. Nat. Commun. 2021;12:6540. doi: 10.1038/s41467-021-26750-6. - DOI - PMC - PubMed
    1. Crossfield S.S.R., Marzo-Ortega H., Kingsbury S.R., Pujades-Rodriguez M., Conaghan P.G. Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open. 2021;7:e001888. doi: 10.1136/rmdopen-2021-001888. - DOI - PMC - PubMed
    1. Watad A., McGonagle D., Anis S., Carmeli R., Cohen A.D., Tsur A.M., Ben-Shabat N., Bragazzi N.L., Lidar M., Amital H. TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: Results from a nationwide study. Pharmacol. Res. 2022;182:106325. doi: 10.1016/j.phrs.2022.106325. - DOI - PubMed
    1. Dubash S., Bridgewood C., McGonagle D., Marzo-Ortega H. The advent of IL-17A blockade in ankylosing spondylitis: Secukinumab, ixekizumab and beyond. Expert Rev. Clin. Immunol. 2019;15:123–134. doi: 10.1080/1744666X.2019.1561281. - DOI - PubMed

Publication types